Xiidra is a preservative-free, sterile solution with a neutral pH range of 7.0 to 8.01
Contact lenses should be removed before using Xiidra and may be put back in 15 minutes after using the treatment1
Systemic exposure following topical ophthalmic administration to Xiidra was low in studies1
Want to learn more about Xiidra and Shire?
Tell us your e-mail address:
NIICEThanks for registering. We’re really looking forward to sending you updates.
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are about to leave this site. Please be advised that Shire does not have control over the content or presentation of the site you are about to view. The Shire Privacy Notice does not apply.
